Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 16/20 | 0.46 |
| ▸ | ICAM1 | P05362 | 16/20 | 0.46 |
| ▸ | ITGAL | P20701 | 16/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30083821 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL30279451 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL23978931 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL29019146 | 1.00 | ITGB2 (0.46) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL23978775 | 0.90 | EPHX2 (0.42) | ITGB2ICAM1ITGALEPHX2TAS1R3 | |
| SCHEMBL24803392 | 0.90 | EPHX2 (0.42) | ITGB2ICAM1ITGALEPHX2TAS1R3 | |
| SCHEMBL30083857 | 0.90 | EPHX2 (0.42) | ITGB2ICAM1ITGALEPHX2TAS1R3 | |
| SCHEMBL26476186 | 0.88 | ITGB2 (0.48) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL26476093 | 0.88 | ITGB2 (0.48) | ITGB2ICAM1ITGALEPHX2ALDH1A1 | |
| SCHEMBL24803394 | 0.87 | EPHX2 (0.48) | EPHX2ALDH1A1TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| CN-115916176-A | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | 加利福尼亚大学董事会 | 2023-04-04 | — | — | CN | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | ITGB2 2/4885ICAM1 21/4885ITGAL 7/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | ITGB2 2/4885ICAM1 21/4885ITGAL 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.